Back to News
Market Impact: 0.25
BioNTech Lifts Outlook Boosted by Cancer Drug Milestone Payments
Source: Bloomberg
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
BioNTech nudged its full-year sales outlook higher, supported by milestone payments from its cancer drug partnership with Bristol Myers Squibb. The article provides no amount for the outlook increase or milestone payments.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BMY0.10
BNTX0.40
More News
- BTIG raises Tempus AI stock price target to $100 on data deals
- Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide